Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 3.97
TPI's Cash to Debt is ranked higher than
54% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. TPI: 3.97 )
Ranked among companies with meaningful Cash to Debt only.
TPI' s 10-Year Cash to Debt Range
Min: 1.04  Med: 8.89 Max: No Debt
Current: 3.97
Equity to Asset 0.96
TPI's Equity to Asset is ranked higher than
98% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. TPI: 0.96 )
Ranked among companies with meaningful Equity to Asset only.
TPI' s 10-Year Equity to Asset Range
Min: -0.94  Med: 0.90 Max: 0.96
Current: 0.96
-0.94
0.96
Interest Coverage 6.85
TPI's Interest Coverage is ranked lower than
83% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2065.49 vs. TPI: 6.85 )
Ranked among companies with meaningful Interest Coverage only.
TPI' s 10-Year Interest Coverage Range
Min: 6.85  Med: 150.62 Max: 9999.99
Current: 6.85
6.85
9999.99
F-Score: 2
Z-Score: 2.49
M-Score: -3.10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -0.75
TPI's Operating margin (%) is ranked lower than
74% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. TPI: -0.75 )
Ranked among companies with meaningful Operating margin (%) only.
TPI' s 10-Year Operating margin (%) Range
Min: -628.57  Med: 13.80 Max: 23.06
Current: -0.75
-628.57
23.06
Net-margin (%) -8.14
TPI's Net-margin (%) is ranked lower than
80% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. TPI: -8.14 )
Ranked among companies with meaningful Net-margin (%) only.
TPI' s 10-Year Net-margin (%) Range
Min: -628.57  Med: 9.88 Max: 18.59
Current: -8.14
-628.57
18.59
ROE (%) -2.82
TPI's ROE (%) is ranked lower than
73% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. TPI: -2.82 )
Ranked among companies with meaningful ROE (%) only.
TPI' s 10-Year ROE (%) Range
Min: -108.64  Med: 14.46 Max: 36.26
Current: -2.82
-108.64
36.26
ROA (%) -2.61
TPI's ROA (%) is ranked lower than
73% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. TPI: -2.61 )
Ranked among companies with meaningful ROA (%) only.
TPI' s 10-Year ROA (%) Range
Min: -44  Med: 12.91 Max: 32.35
Current: -2.61
-44
32.35
ROC (Joel Greenblatt) (%) -5.83
TPI's ROC (Joel Greenblatt) (%) is ranked lower than
73% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. TPI: -5.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TPI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -338.46  Med: 43.60 Max: 127.19
Current: -5.83
-338.46
127.19
Revenue Growth (3Y)(%) -21.00
TPI's Revenue Growth (3Y)(%) is ranked lower than
91% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. TPI: -21.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TPI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 6.85 Max: 457.2
Current: -21
0
457.2
EBITDA Growth (3Y)(%) -51.70
TPI's EBITDA Growth (3Y)(%) is ranked lower than
95% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. TPI: -51.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TPI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -7.60 Max: 19.1
Current: -51.7
0
19.1
» TPI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

TPI Guru Trades in Q2 2014

Jim Simons 680,100 sh (+9.68%)
» More
Q3 2014

TPI Guru Trades in Q3 2014

Jim Simons 714,400 sh (+5.04%)
» More
Q4 2014

TPI Guru Trades in Q4 2014

Jim Simons 737,900 sh (+3.29%)
» More
Q1 2015

TPI Guru Trades in Q1 2015

Jim Simons 771,600 sh (+4.57%)
» More
» Details

Insider Trades

Latest Guru Trades with TPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.10
TPI's P/B is ranked higher than
99% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. TPI: 0.10 )
Ranked among companies with meaningful P/B only.
TPI' s 10-Year P/B Range
Min: 0.1  Med: 0.36 Max: 2.76
Current: 0.1
0.1
2.76
P/S 0.26
TPI's P/S is ranked higher than
95% of the 649 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.43 vs. TPI: 0.26 )
Ranked among companies with meaningful P/S only.
TPI' s 10-Year P/S Range
Min: 0.19  Med: 0.48 Max: 3.54
Current: 0.26
0.19
3.54
Shiller P/E 1.11
TPI's Shiller P/E is ranked higher than
99% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.83 vs. TPI: 1.11 )
Ranked among companies with meaningful Shiller P/E only.
TPI' s 10-Year Shiller P/E Range
Min: 1.11  Med: 2.10 Max: 3.35
Current: 1.11
1.11
3.35
Current Ratio 5.77
TPI's Current Ratio is ranked higher than
82% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. TPI: 5.77 )
Ranked among companies with meaningful Current Ratio only.
TPI' s 10-Year Current Ratio Range
Min: 0.06  Med: 4.70 Max: 6.89
Current: 5.77
0.06
6.89
Quick Ratio 4.38
TPI's Quick Ratio is ranked higher than
77% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. TPI: 4.38 )
Ranked among companies with meaningful Quick Ratio only.
TPI' s 10-Year Quick Ratio Range
Min: 0.06  Med: 4.11 Max: 6.15
Current: 4.38
0.06
6.15
Days Inventory 91.78
TPI's Days Inventory is ranked higher than
62% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.49 vs. TPI: 91.78 )
Ranked among companies with meaningful Days Inventory only.
TPI' s 10-Year Days Inventory Range
Min: 29.51  Med: 44.12 Max: 62.46
Current: 91.78
29.51
62.46
Days Sales Outstanding 24.19
TPI's Days Sales Outstanding is ranked higher than
87% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.86 vs. TPI: 24.19 )
Ranked among companies with meaningful Days Sales Outstanding only.
TPI' s 10-Year Days Sales Outstanding Range
Min: 34.64  Med: 48.65 Max: 71.15
Current: 24.19
34.64
71.15

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.25
TPI's Price/Net Cash is ranked higher than
97% of the 181 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.71 vs. TPI: 1.25 )
Ranked among companies with meaningful Price/Net Cash only.
TPI' s 10-Year Price/Net Cash Range
Min: 0.71  Med: 3.02 Max: 9.48
Current: 1.25
0.71
9.48
Price/Net Current Asset Value 0.41
TPI's Price/Net Current Asset Value is ranked higher than
98% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.66 vs. TPI: 0.41 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
TPI' s 10-Year Price/Net Current Asset Value Range
Min: 0.34  Med: 0.99 Max: 4.12
Current: 0.41
0.34
4.12
Price/Tangible Book 0.13
TPI's Price/Tangible Book is ranked higher than
99% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.32 vs. TPI: 0.13 )
Ranked among companies with meaningful Price/Tangible Book only.
TPI' s 10-Year Price/Tangible Book Range
Min: 0.19  Med: 0.60 Max: 2.86
Current: 0.13
0.19
2.86
Price/Projected FCF 0.14
TPI's Price/Projected FCF is ranked higher than
99% of the 321 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. TPI: 0.14 )
Ranked among companies with meaningful Price/Projected FCF only.
TPI' s 10-Year Price/Projected FCF Range
Min: 0.16  Med: 0.26 Max: 0.43
Current: 0.14
0.16
0.43
Price/Median PS Value 0.54
TPI's Price/Median PS Value is ranked higher than
92% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. TPI: 0.54 )
Ranked among companies with meaningful Price/Median PS Value only.
TPI' s 10-Year Price/Median PS Value Range
Min: 0.43  Med: 1.19 Max: 5.83
Current: 0.54
0.43
5.83
Earnings Yield (Greenblatt) (%) -769.20
TPI's Earnings Yield (Greenblatt) (%) is ranked lower than
100% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. TPI: -769.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TPI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -769.2  Med: 32.15 Max: 6688.7
Current: -769.2
-769.2
6688.7
Forward Rate of Return (Yacktman) (%) -40.90
TPI's Forward Rate of Return (Yacktman) (%) is ranked lower than
97% of the 308 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.88 vs. TPI: -40.90 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TPI' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -36.5  Med: 3.90 Max: 31.7
Current: -40.9
-36.5
31.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:60T.Germany,
Tianyin Pharmaceutical Co Inc previously called Viscorp, Inc., was originally formed as a limited liability company under the laws of the State of Delaware on August 20, 2002. The Company is engaged in the development, manufacturing, marketing and sales of patented biopharmaceutical medicines, branded generics, modernized traditional Chinese medicines, and other pharmaceuticals in China. The Company currently manufactures a portfolio of 58 products, 24 of which are listed in the National Medical Reimbursement List and 10 are listed in the National Essential Drug List of China. It sells its products via regional distributors as well as directly to the hospitals, clinics, and pharmacies in China. Its geographical location at Sichuan province facilitates an access to high-grade raw ingredients for both raw materials for chemical medicine as well as Chinese medicines. The traditional Chinese medicine (TCM) industry in China is fragmented and intensely competitive. It faces competition from domestic TCM manufacturers, as well as domestic and foreign pharmaceuticals providers with similar therapeutic effects. China's pharmaceutical industry is regulated by the government. The primary regulatory authority is the CFDA, including its provincial and local branches, by which it is subject to regulation and oversight. China's healthcare laws stipulate the production and sale of pharmaceuticals in China, covering the manufacturing, distributing, packaging, pricing and advertising of pharmaceutical products. It is also subject to other Chinese laws and regulations that are applicable to business operators, manufacturers and distributors in general.
» More Articles for TPI

Headlines

Articles On GuruFocus.com
5 year low Apr 21 2013 
8 Healthcare Dividend Stocks Close To 52-Week Low Sep 03 2011 
18 Low Beta Healthcare Stocks With Best Dividend Yields Jul 02 2011 
High Yields In Healthcare Sector May 26 2011 
Tianyin Pharmaceutical Co., Inc. Receives Production License to Launch Tongbianling Capsules Dec 22 2008 

More From Other Websites
4:09 pm Tianyin Pharma receives another notice from the Exchange in connection with the filing of... Jul 30 2015
TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements Jul 30 2015
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Jul 17 2015
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 14 2015
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 25 2015
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws;... Jun 22 2015
Buchang to Increase Stake in Tianyin-Buchang Alliance Jun 15 2015
Tianyin Pharmaceutical Announces Further Updates on Joint Venture with Buchang Pharma Jun 12 2015
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... May 26 2015
TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE... May 26 2015
TPI Holds Annual Meeting of Shareholders on May 25, 2015 at Chengdu, China Apr 22 2015
TIANYIN PHARMACEUTICAL CO., INC. Financials Mar 19 2015
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 10-Q, Quarterly Report Mar 13 2015
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Feb 26 2015
TPI Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements Feb 26 2015
JCM Plans for FDA certification Process for International Business Development Feb 17 2015
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 8-K/A, Other Events, Financial Statements and... Feb 06 2015
TPI to Form Strategic Alliance with Buchang Pharma Feb 06 2015
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 8-K, Change in Directors or Principal Officers Jan 28 2015
TPI's JCM Updates on Import Registration for International Clients Jan 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK